The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chen S, Wu Z, Shi F, et al. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol. 2022;148(8):2115–2125. doi:10.1007/s00432-021-03767-4
   PubMed Web of Science ®Google Scholar
• Han Z, Yang F, Zhang Y, et al. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: a retrospective study. Front Oncol. 2022;12:1029951. doi:10.3389/fonc.2022.1029951
   PubMed Web of Science ®Google Scholar
• Wang WJ, Liu ZH, Wang K, et al. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: a multicenter, retrospective study. Cancer Med. 2023;12(10):11513–11524. doi:10.1002/cam4.5880
   PubMed Web of Science ®Google Scholar
• Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. doi:10.3389/fimmu.2022.848387
   PubMed Web of Science ®Google Scholar
• Lee PC, Wu CJ, Hung YW, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6):e004779. doi:10.1136/jitc-2022-004779
   PubMed Web of Science ®Google Scholar
• Derosa L, Routy B, Desilets A, et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology. Cancer Discov. 2021;11(10):2396–2412. doi:10.1158/2159-8290.CD-21-0236
   PubMed Web of Science ®Google Scholar
• Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8(4):351–358. doi:10.1080/19490976.2017.1284732
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi:10.1136/gutjnl-2015-310376
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Kichenadasse G, McKinnon RA, et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022;126(1):42–47. doi:10.1038/s41416-021-01606-4
   PubMed Web of Science ®Google Scholar
• Rassy E, Dalban C, Colomba E, et al. Efficacy and safety of concomitant proton pump inhibitor and nivolumab in renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter Phase II study. Clin Genitourin Cancer. 2022;20(5):488–494. doi:10.1016/j.clgc.2022.07.003
   PubMed Web of Science ®Google Scholar
• Jun T, Ozbek U, Dharmapuri S, et al. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211010937. doi:10.1177/17588359211010937
   Web of Science ®Google Scholar
• Delmas D, Hermetet F, Aires V. PD-1/PD-L1 checkpoints and resveratrol: a controversial new way for a therapeutic strategy. Cancers. 2021;13(18):4509. doi:10.3390/cancers13184509
   PubMed Web of Science ®Google Scholar
• Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184. doi:10.1186/s13046-021-01987-7
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tucci M, Adamo V, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8(2):e001361. doi:10.1136/jitc-2020-001361
   PubMed Web of Science ®Google Scholar
• Lopes S, Pabst L, Dory A, et al. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Front Immunol. 2023;14:1070076. doi:10.3389/fimmu.2023.1070076
   PubMedGoogle Scholar
• Qin BD, Jiao XD, Zhou XC, et al. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology. 2021;10(1):1929727. doi:10.1080/2162402X.2021.1929727
   PubMed Web of Science ®Google Scholar
• Chen B, Yang C, Dragomir MP, et al. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221111703. doi:10.1177/17588359221111703
   Web of Science ®Google Scholar
• Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710. doi:10.1038/nrgastro.2017.117
   PubMed Web of Science ®Google Scholar
• Clooney AG, Bernstein CN, Leslie WD, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–984. doi:10.1111/apt.13568
   PubMed Web of Science ®Google Scholar
• Zhou CB, Zhou YL, Fang JY. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer. 2021;7(7):647–660. doi:10.1016/j.trecan.2021.01.010
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int. 2019;13(2):234–244. doi:10.1007/s12072-019-09932-9
   PubMed Web of Science ®Google Scholar
• Joo EJ, Cheong HS, Kwon MJ, Sohn W, Kim HN, Cho YK. Relationship between gut microbiome diversity and hepatitis B viral load in patients with chronic hepatitis B. Gut Pathog. 2021;13(1):65. doi:10.1186/s13099-021-00461-1
   PubMed Web of Science ®Google Scholar
• Zhu Q, Xia P, Zhou X, et al. Hepatitis B virus infection alters gut microbiota composition in mice. Front Cell Infect Microbiol. 2019;9:377. doi:10.3389/fcimb.2019.00377
   PubMed Web of Science ®Google Scholar
• Zhou W, Luo J, Xie X, et al. Gut microbiota dysbiosis strengthens Kupffer cell-mediated hepatitis B virus persistence through inducing endotoxemia in mice. J Clin Transl Hepatol. 2022;10(1):17–25. doi:10.14218/JCTH.2020.00161
   PubMed Web of Science ®Google Scholar
• Pan S, Yu Y, Wang S, et al. Correlation of HBV DNA and hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with HBV infection undergoing PD-1 inhibition combinational therapy. Front Immunol. 2022;13:892618. doi:10.3389/fimmu.2022.892618
   PubMed Web of Science ®Google Scholar
• Kalathil SG, Thanavala Y. Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches. Cells. 2021;10(6):1332. doi:10.3390/cells10061332
   PubMed Web of Science ®Google Scholar
• Deng R, Zhang H, Li Y, Shi Y. Effect of antacid use on immune checkpoint inhibitors in advanced solid cancer patients: a systematic review and meta-analysis. J Immunother. 2023;46(2):43–55. doi:10.1097/CJI.0000000000000442
   PubMed Web of Science ®Google Scholar
• Miura K, Sano Y, Niho S, et al. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer. 2021;12(13):1983–1994. doi:10.1111/1759-7714.14001
   PubMed Web of Science ®Google Scholar
• Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol. 2021;12:716317. doi:10.3389/fimmu.2021.716317
   PubMed Web of Science ®Google Scholar
• Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474–484. doi:10.1016/j.ejca.2021.08.036
   PubMed Web of Science ®Google Scholar